International Journal of Nanomedicine · 2013 · 35 citations · 48 references
Life SciencesBiotechnologyImmunologyAdaptive ImmunityImmunizationVaccinologyHumoral ImmunitySubunit VaccinesVaccine DeliveryVaccine Delivery SystemsVaccine FormulationVirus-like Particle VaccinesAntigen Presenting CellsAntigen-specific Immune ResponseNanoparticle Subunit VaccinesNanoparticle Vaccine DeliveryNanoparticle Vaccine FormulationsNanoparticle Vaccine PlatformsNanoparticlesVaccine Delivery Formulations
Nano-sized hepatitis B virus core virus-like particles (HBc-VLP) are suitable for uptake by antigen-presenting cells. Mycobacterium tuberculosis antigen culture filtrate protein 10 (CFP-10) is an important vaccine candidate against tuberculosis. The purified antigen shows low immune response without adjuvant and tends to have low protective efficacy. The present study is based on the assumption that expression of these proteins on HBc nanoparticles would provide higher protection when compared to the native antigen alone. The cfp-10 gene was expressed as a fusion on the major immunodominant region of HBc-VLP, and the immune response in Balb/c mice was studied and compared to pure proteins, a mixture of antigens, and fusion protein-VLP, all without using any adjuvant. The humoral, cytokine, and splenocyte cell proliferation responses suggested that the HBc-VLP bearing CFP-10 generated an antigen-specific immune response in a Th1-dependent manner. By virtue of its self-adjuvant nature and ability to form nano-sized particles, HBc-VLPs are an excellent vaccine delivery system for use with subunit protein antigens identified in the course of recent vaccine research.
48
Efficacy of BCG Vaccine in the Prevention of Tuberculosis
Graham A. Colditz · JAMA · 1994 · 1.9K citations
Veterinary Medicine, Infectious Diseases, Preventive Medicine +17
JoAnne L. Flynn, Marsha M. Goldstein, K J Triebold et al. · Proceedings of the National Academy of Sciences · 1992 · 783 citations · Full text